Daniel M. Klass
27 works · 2,248 citations · h-index 12
Top works
- Integrated digital error suppression for improved detection of circulating tumor DNA
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
- Proteome-Wide Search Reveals Unexpected RNA-Binding Proteins in Saccharomyces cerevisiae
- Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus
- Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Quantitative proteomic analysis reveals concurrent RNA–protein interactions and identifies new RNA-binding proteins in Saccharomyces cerevisiae
- ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
- Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).
- Whi3, an S. cerevisiae RNA-Binding Protein, Is a Component of Stress Granules That Regulates Levels of Its Target mRNAs
- Identification and genetic manipulation of human and mouse oesophageal stem cells
- Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
- Quantitative PCR–Based Method to Assess Cell-Free DNA Quality, Adjust Input Mass, and Improve Next-Generation Sequencing Assay Performance
- Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
- Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma
- Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.
- Improved Discovery of Molecular Interactions in Genome-Scale Data with Adaptive Model-Based Normalization
- Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma
- Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects.
- Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.
- Abstract 3379: Assessment of tumor mutation burden using a novel panel design strategy utilizing highly mutated genomic regions